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with L-thyroxine withdrawal
Ablacja resztkowej tarczycy radiojodem u chorych na zróżnicowanego
raka tarczycy (DTC) za pomocą rhTSH — porównanie ze stymulacją endogenną
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Abstract
Introduction: A group of differentiated thyroid carcinoma (DTC) patients receiving post thyroidectomy rhTSH-aided radioiodine treatment
(group I) was compared with patients treated with 131I following endogenous stimulation of TSH (group II) after L-thyroxine withdrawal.
Materials and methods: Group I consisted of 66 patients of mean age 51.7 ± 16.2 years (58 females and 8 males). Group II included
76 patients of mean age 54.8 ± 14.7 years (67 females and 9 males). All patients underwent total thyroidectomy and central lymph node
dissection and additionally lateral lymph node excision, if required. Prior to radioiodine treatment thyroid volume (VT) and 24-hour 131I
uptake were evaluated. TSH and Tg concentrations were measured prior to and after endogenous and exogenous stimulation of TSH.
Whole-body post-therapeutic scintigraphy was evaluated. Basic statistics, W Shapiro-Wilk, Wilcoxon, and U Mann-Whitney tests were
applied.
Results: Median values of VT and of 24-hr 131I uptake in groups I and II were not significantly different. The differences between median
values of serum TSH concentration after stimulation in groups I and II were statistically significant (p < 0.05), respective medians being
100.0 µU/mL (IQR = 107.3) and 78.8 µU/mL (IQR = 47.7). Median values of serum Tg concentrations in groups I and II following TSH
stimulation prior to radioiodine treatment were 2.6 ng/ml (IQR = 8.4) and 4.9 ng/ml (IQR = 12.6), respectively, the difference not being
statistically significant. Following rhTSH treatment no adverse effects were observed compared to LT4 withdrawal.
Conclusions: rhTSH may be safely used for 131I thyroid remnant ablation in low-risk DTC patients.
(Pol J Endocrinol 2010; 61 (5): 474–479)
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Streszczenie
Wstęp: Grupę pacjentów ze zróżnicowanym rakiem tarczycy leczonych 131I za pomocą stymulacji z zastosowaniem rhTSH (grupa I)
porównano z pacjentami leczonymi po endogennej stymulacji TSH (grupa II).
Materiał i metody: Grupa I składała się z 66 chorych (śr. wieku 51,7 ± 16,2 lat, 58 kobiet, 8 mężczyzn). Grupa II składała się z 76 chorych
(śr. wieku 54,8 ± 14,7 lat, 67 kobiet, 9 mężczyzn). Leczenie chirurgiczne polegało na całkowitym wycięciu tarczycy i operacji węzłów
chłonnych przedziału centralnego, a w razie potrzeby także operacji węzłów szyjnych bocznych. Przed leczeniem 131I oceniano objętość
kikutów tarczycy (VT) w badaniu USG oraz 24-godzinny wychwyt 131I nad szyją. Stężenie TSH i Tg oznaczano przed i po stymulacji endo-
i egzogennej TSH. Oceniano również gromadzenie 131I w scyntygrafii poterapeutycznej całego ciała. Analizę statystyczną przeprowadzo-
no za pomocą statystyki opisowej, testu W Shapiro-Wilka, testu Wilcoxona i testu U Mann-Whitneya.
Wyniki: Mediany objętości tarczycy oraz mediany wychwytu 131I w grupie I i II nie różniły się znamiennie statystycznie. Mediany stężeń
TSH w surowicy po stymulacji w grupie I i II różniły się istotnie (p < 0,05) i wynosiły odpowiednio 100,0 µj./ml (IQR = 107,3) i 78,8 µj./ml
(IQR = 47,7). Mediany stężeń Tg w surowicy po stymulacji w grupie I i II przed leczeniem 131I wynosiły odpowiednio 2,6 ng/ml (IQR = 8,4)
i 4,9 ng/ml (IQR = 12,6) i nie różniły się znamiennie statystycznie. Nie obserwowano działań niepożądanych po zastosowaniu rhTSH
w porównaniu z leczeniem po odstawieniu L-tyroksyny.
Wnioski: rhTSH może być bezpiecznie stosowane do ablacji kikutów tarczycy radiojodem 131I u pacjentów ze zróżnicowanym rakiem
tarczycy z grupy niskiego ryzyka. (Endokrynol Pol 2010; 61 (5): 474–479)
Słowa kluczowe: zróżnicowany rak tarczycy, leczenie radiojodem, rhTSH
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Introduction
It is generally understood that proliferation of thyroid
follicular cells, normal and transformed, is regulated by
TSH. Therefore, patients diagnosed with differentiated
thyroid carcinoma (DTC) who have undergone total
thyroidectomy are treated with TSH-suppressing dos-
es of L-thyroxine (LT4). The low serum TSH concentra-
tion required in the interim has to be elevated for adju-
vant 131I radioiodine thyroid remnant ablation and ra-
dioiodine therapy of disseminated disease. In order to
achieve high serum TSH concentrations [1] LT4 has to
be withdrawn, causing severe hypothyroidism with all
its costs and comorbidities. Recently, recombinant hu-
man thyrotropin (rhTSH) was introduced in differenti-
ated thyroid carcinoma treatment and follow-up as
a safe and effective alternative to LT4 withdrawal. The
first clinical applications of rhTSH, introduced in the
US in 1998 and in Europe in 2001, were in diagnostics,
to evaluate stimulated thyroglobulin (Tg) concentrations
and 131I whole-body scans (WBS). After publication of
a multicentre, randomized, controlled study [2], the
EMEA (European Medicine Agency) in 2005 and the
FDA (Food and Drug Administration) in 2007 approved
rhTSH-aided ablation of thyroid remnants with 100 mCi
of 131I in low-risk patients. This was later extended to
intermediate-risk patients with lymph node metastas-
es [3]. 131I treatment aided by rhTSH has not yet been
approved for metastatic patients; however, several ob-
servations confirming the safety and efficacy of this
treatment in advanced DTC have already been pub-
lished [4, 5]. Recombinant human TSH stimulation of-
fers better quality of life. It is also a cost-effective meth-
od, the high cost of rhTSH being offset by shorter sick-
leave in patients treated. Finally, application of this
method leads to lower absorbed whole-body dose, due
to higher renal clearance, enabling higher therapeutic
activities to be applied. In 2009 all DTC patients of our
Clinic of Endocrinology were treated for the first time
with the aid of recombinant human TSH.
We present a comparison between two groups of
patients with differentiated thyroid carcinoma treated
with radioiodine 131I in 2009 following exogenous stim-
ulation of TSH (group I), and in 2008 following endog-
enous stimulation (group II).
Material and methods
Group I consisted of 66 patients (58 females and 8 males)
of mean age 51.7 ± 16.2 years. Papillary thyroid cancer
was diagnosed in 58 patients (87.9%) and follicular can-
cer in 8 patients (12.1%). Group II consisted of 76 pa-
tients (67 females and 9 males) of mean age 54.8 ±
± 14.7 years, with papillary thyroid cancer diagnosed
in 60 patients (78.9%) and follicular cancer in 13 patients
(17.1%). Other variants of thyroid cancer (among them,
Hürthle cell carcinoma) were diagnosed in 3 patients
(3.9%) from this group. All patients in both groups un-
derwent total thyroidectomy with central lymph node
resection. Enlarged lateral lymph nodes, as stated in
preoperative physical or USG examination, were also
resected. The surgically obtained specimens underwent
histopathological and additional immunohistochemical
examination to state the presence of Tg in the lateral
lymph nodes. In rhTSH-stimulated group I, the pres-
ence of metastases in the central lymph nodes was stat-
ed in 13/66 (19.7%) patients and the presence of me-
tastases in lateral lymph nodes in 3/66 (4.5%) patients.
In group II of the patients treated with endogenous TSH
stimulation, the presence of metastases in the central
lymph nodes was stated in 9/76 (11.8%) patients and
the presence of metastases in lateral lymph nodes in
2/76 (2.6%) patients. Prior to surgery, no distant me-
tastases were stated in either group of patients.
LT4 treatment was commenced immediately after
surgery to suppress TSH levels. For radioiodine treat-
ment, in group I on LT4 therapy, patients were admin-
istered 0.9 mg i.m. of rhTSH (Thyrogen, Genzyme) on
two consecutive days and received radioiodine 24 hours
after the second injection, according to a procedure
described elsewhere [6]. In group II, LT4 was withdrawn
four weeks prior to 131I treatment.
In all patients prior to radioiodine treatment, thy-
roid volume (VT) was evaluated by sonography and
24-hr 131I (0.1 mCi; 4 MBq) uptake over the neck was
measured. Oral administration of 100 mCi (3700 MBq)
was performed immediately after the neck scan was
completed. Six days after 131I administration post-ther-
apeutic whole-body scintigraphy (WBS) was evaluated
by a dual-head computed gamma camera equipped
with high energy collimators (Siemens).
TSH (ECL, Roche) and Tg (ECL, Roche) concentra-
tions were measured prior to and after exogenous stim-
ulation of TSH, according to the general scheme of rhT-
SH trials [6]. In group II, TSH and Tg were measured
prior to 131I administration. The presence of anti-Tg an-
tibodies was evaluated (ECL, Roche).
Basic statistics, W Shapiro-Wilk, Wilcoxon, U Mann-
Whitney, ANOVA Friedman, and chi2 tests were ap-
plied.
Results
No significant differences with respect to VT and 24-hr
131I uptake were found between patients in group I (rhTSH
stimulation) and those in group II (LT4 withdrawal), nor
was the age at which DTC was diagnosed different in
either group (Table I). In both groups of patients pooled
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together (n = 142) the age interval at which differentia-
ted thyroid carcinoma occurred most frequently was
between 40 and 70 years of age, concerning about 60%
of these patients. The mean age at which papillary or
follicular cancer was diagnosed in our patients was sig-
nificantly different: 52.0 ± 15.2 and 60.0 ± 16.1 years,
respectively (p < 0.05) (Fig. 1).
Thyroid cancer staging was performed in all patients
of each group according to AJCC/UICC criteria [7]. All
patients below the age of 45 years in group I (n = 19)
and group II (n = 18) were qualified as stage I. Patients
over 45 years of age in group I (n = 38) were, in most
cases (n = 23, 60.5%), also assigned stage I. In 3 patients
(7.9%) stage II, and in 9 patients (23.7%) stage III was
assigned, while the remaining 3 patients (7.9 %) were
classified as stage IV. In 9 patients, DTC staging was
not possible as the tumour size could not be determined
(pTx). Patients over 45 years of age in group II (n = 51)
were, in most cases (n = 33, 64.7%), assigned stage I. In
7 patients (13.7%) stage II, and in 9 patients (17.6%) stage
III was assigned, while the remaining 2 patients (3.9%)
were classified as stage IV. In 7 patients, DTC staging
was not possible as the tumour size could not be deter-
mined (pTx). No difference in DTC staging was stated
between the studied groups of patients, as based on
contingency analysis (c2 test), p > 0.05.
After LT4 withdrawal or 24 hours after rhTSH injec-
tion, increased levels of TSH were observed. The dif-
ferences between median values of TSH concentration
prior to and after stimulation in group I and group II
were statistically significant (p < 0.001), as expected.
Immediately before rhTSH injection, serum TSH con-
centration was significantly higher in the hypothyroid
group II 78.8 µU/mL ( IQR = 47.7), as compared to group
I 0.1 µU/mL (IQR = 0.9) (p < 0.001). After stimulation,
the differences between median values of TSH concen-
trations in group I: 100.0 µU/mL (IQR = 107.3) and
group II: 78.8 µU/mL (IQR = 47.7) were statistically sig-
nificant (p < 0.001) (Fig. 2).
In group I of the patients which underwent rhTSH-
aided 131I treatment, a gradual increase in serum Tg con-
centration was observed, commencing with a median
Figure 1. Mean patient age at DTC histopathology diagnosis
Rycina 1. Średni wiek zachorowania pacjentów na DTC w zależności
od rozpoznania histopatologicznego
Figure 2. TSH serum concentration after endogenous and rhTSH
stimulation in the studied groups of patients
Rycina 2. Stężenie TSH w surowicy po stymulacji endogennej
i rhTSH w badanych grupach pacjentów
Table I. Clinical characteristics of the studied patient groups
Tabela I. Charakterystyka kliniczna badanych grup pacjentów
Group of patients N Age at diagnosis (yrs) × ± SD Thyroid volume (VT) [mL] 131I uptake (%)
Group I  rhTSH 66 51.7 ± 16.2 0.5 ± 1.1 5.5 ± 3.1
Group II LT4withdrawal 76 54.8 ± 14.8 0.8 ± 1.1 8.0 ± 5.4
p (t-test)  > 0.05  > 0.05  > 0.05
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value of 0.1 ng/mL (IQR = 1.0) up to median values of
2.6 ng/mL (IQR = 8.4) and 15.2 ng/mL (IQR = 60.2)
24 hrs and 72 hrs after rhTSH administration, respec-
tively. All differences in these median values were sta-
tistically significant (p < 0.0001) (Fig. 3).
The median value of serum Tg concentrations in
group I 24 hours after the last rhTSH administration
(2.6 ng/mL, IQR = 8.4) was found to be lower than the
median value of Tg concentration following LT4 withdrawal
observed in group II (4.9 ng/mL, IQR = 12.6), the differ-
ence not being statistically significant (p > 0.05) (Fig. 4).
However, the median value of Tg concentrations in
group I (15.2 ng/mL, IQR = 60.2) 72 hours after the last
rhTSH administration was found to be significantly high-
er than the value (4.9 ng/mL; IQR = 12.6) observed in
group II following LT4 withdrawal (p < 0.001) (Fig. 5).
The median levels of anti-Tg antibodies were
25.7 IU/mL (IQR = 126.4) and 17.9 IU/mL (IQR = 73.9)
in groups I and group II, respectively, the difference
not being statistically significant (p > 0.05).
On evaluation of post-therapeutic WBS, accumula-
tion of tracer in thyroid remnants, was found in 98.5%
and 98.7% of patient in groups I and II, respectively.
The quality of post-therapeutic WBS after rhTSH-aided
131I treatment was comparable to that of WBS following
endogenous stimulation (Fig. 6).
In group I following rhTSH stimulated radioiodine
therapy, further diagnostics was required in 11 patients
(16.7%), in whom tracer accumulation was present in
the lungs (2 patients), mediastinum (3 patients), and
outside thyroid bed in the neck (6 patients). In none of
the patients distant metastases were observed, based
on CT and MRI scans. Since Tg concentration below
1 ng/ml was observed in all of these patients, non-spe-
cific accumulation of 131I in the lungs was assumed. Trac-
er accumulation in the mediastinum most probably cor-
responded with 131I uptake in the thymus remnants.
Lymph node metastases were identified in 6 patients
of group I, as verified by neck USG and FNAB. Thus,
finally, in 6 cases the patients were rediagnosed with
lymph node metastases. In group II, following endoge-
nous TSH stimulation after LT4 withdrawal, 4 patients
(5.3%) required verification due to 131I uptake in the
lungs (2 patients), mediastinum (1 patient), and neck
(1 patient). Distant lung metastases were found in one
patient, who demonstrated high serum Tg concentra-
tion (508.8 ng/ml). In 1 patient of group II, lymph node
metastases were identified.
No correlations between volume of thyroid rem-
nants and serum Tg concentration nor between 131I up-
take in the thyroid bed and Tg concentration prior to
rhTSH stimulation were found.
In patients of group II, compared to patients of group I,
signs and symptoms of hypothyroidism were observed.
Following rhTSH treatment no adverse effects were
noted.
Figure 3. Increase of Tg serum concentration after rhTSH
stimulation over 72 hrs observation time in group II patients
Rycina 3. Wzrost stężenia Tg w surowicy pacjentów grupy II, po
stymulacji rhTSH w czasie 72 godzin obserwacji
Figure 4. Tg serum concentration 24 hrs after rhTSH stimulation and
after endogenous TSH stimulation in the studied groups of patients
Rycina 4. Wzrost stężenia Tg w surowicy 24 godziny po
stymulacji rhTSH i po stymulacji endogennej TSH w badanych
grupach pacjentów
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Discussion
Treatment of differentiated thyroid carcinoma (DTC)
consists of total thyroidectomy followed by radioiod-
ine 131I thyroid remnant ablation and TSH suppression
Figure 6. Post-therapeutic WBS after rhTSH-aided 131I treatment.
Tracer uptake in neck lymph nodes outside the thyroid bed
Rycina 6. WBS poterapeutyczna po leczeniu 131I wspomaganym
stymulacją rhTSH. Gromadzenia znacznika w węzłach chłonnych
szyi poza lożą tarczycy
Figure 5. Tg serum concentration 72 hrs after rhTSH stimulation
and after endogenous TSH stimulation in the studied groups of
patients
Rycina 5. Wzrost stężenia Tg w surowicy 72 godziny po
stymulacji rhTSH i po stymulacji endogennej TSH w badanych
grupach pacjentów
with LT4 [8, 9]. The rationale for 131I ablation is to de-
stroy any normal thyroid tissue which produces thy-
roglobulin, and to eliminate any microscopic foci of
DTC. This procedure increases the specificity and sen-
sitivity of Tg follow-up. In order to successfully apply
131I treatment the TSH level must be elevated to above
30 µU/mL [1, 8], which can be achieved either by LT4
withdrawal or by application of recombinant human
TSH. However, LT4 withdrawal induces clinically overt
hypothyroidism with all its consequences [10]. There-
fore, as soon as rhTSH-aided 131I therapy became avail-
able in 2009, all DTC patients of our clinic were treated
and diagnosed under continued LT4 treatment.
In this work, we compared a group of patients with
differentiated thyroid carcinoma treated with131I in 2009,
where radioiodine therapy following rhTSH stimula-
tion could be applied with a group of patients treated
in 2008 following endogenous stimulation. Our com-
parison is between groups similar with respect to age
and quality of surgery, as indicated by no significant
differences in VT and 24-hr 131I uptake in patients of
either group. Nor was a difference in DTC staging stat-
ed between the studied groups of patients.
The mean age of all our patients at diagnosis was
about 10 years greater than that of the patients analyzed
by Elisei et al. [11] and close to the value listed in the
SEER base [12]. Additionally, the female to male ratio
was different (7:1 in our group of patients versus 3:1),
probably due to significant differences in the numbers
of patients analyzed [11]. Dividing our patients accord-
ing to histopathology results, those with follicular can-
cer were found to be about 10 years older than patients
with papillary cancer, the difference being statistically
significant and in agreement with general epidemio-
logical data [13]. The frequency of papillary and follicu-
lar cancer was similar to that found in the published
data (88% v. 12%) [11].
Some 60 % of our patients were diagnosed with thy-
roid cancer at the age of 40–70 years, in agreement with
the age interval at which DTC occurred most frequent-
ly according to the SEER register [12].
Some 65% of our patients were qualified as stage I
according to AJCC/UICC criteria [7], which agrees with
the respective statistics of Elisei et al. [11] based on
a large group of 4187 patients analysed at one Italian
centre. However, our estimate of 3.5% (5/142) of patients
qualified as stage IV does not agree with their estimates
(10% of stage IV patients).
Recombinant human TSH stimulates the production
of thyroglobulin and increases 131I uptake in thyroid
cancer patients remaining on LT4 suppression of TSH.
Since the efficacy of rhTSH is comparable with LT4 with-
drawal, it is now used in clinical practice for thyroid rem-
nant ablation [2] and for follow-up of DTC patients [14].
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Immediately before rhTSH injection, serum TSH con-
centration was significantly higher in hypothyroid
group II as compared to group I. A significant increase
in serum TSH concentration in group I was observed
24 hrs after the second rhTSH injection, indicating the
efficacy of stimulation.
Similar behaviour was observed with respect to Tg
concentration. After 24 hrs and after 72 hrs we observed
a statistically significant increase of Tg concentration
compared with the initial value prior to rhTSH admin-
istration.
After 24 hrs post administration of the last dose of
rhTSH we found Tg concentration to be lower than that
in group II of patients after withdrawal of LT4 four
weeks earlier; however, the difference was not statisti-
cally significant.
After 72 hrs post administration of the last dose of
rhTSH we found Tg concentration to be significantly
higher than that in group II of patients who were in-
vestigated after withdrawal of LT4 but prior to 131I ad-
ministration. This observation could be explained by the
effect of 131I administration 24 hrs after the last dose of
rhTSH in patients of group I and the Tg release from
damaged thyroid cells which occurred only in those
patients.
For thyroid remnant ablation in our patients we used
100 mCi (3.7 GBq) 131I therapeutic activity since it was
documented as being associated with a high rate of suc-
cessful ablation in hypothyroid patients [15]. Also, Pa-
cini et al. [2] demonstrated in a randomized, controlled
study that standard activity of 100 mCi (3.7 MBq) is suf-
ficient to ablate thyroid remnants in almost all patients
while using rhTSH stimulation.
Thyroid remnant 131I uptake on post-therapeutic
WBS was seen in virtually all our patients of both
groups, as found by Pacini et al. [2]. In our study 131I
uptake outside the thyroid bed on post-therapeutic WBS
was observed more frequently in the rhTSH stimulated
group (16.7% v. 5.3%) due to 6 patients in whom lymph
node metastases were diagnosed concomitantly with
131I treatment. Ladenson [16] suggests possible greater
sensitivity of WBS and a higher level of Tg stimulation
after withdrawal of LT4, but in his work diagnostic WBS
and stimulated Tg were evaluated in post-ablative pa-
tients. We consider late diagnosis of lymph node me-
tastases in some patients as the cause of the observed
131I lymph node uptake.
We have demonstrated the safety of rhTSH aided
131I primary therapy in DTC as no significant side ef-
fects were reported in group I after the administration
of rhTSH, which is in agreement with the data from
Barbaro et al. [17].
However, the efficacy of thyroid remnant ablation
following LT4 withdrawal and rhTSH-aided treatment
could not yet be evaluated and compared as in the pa-
tients from group I diagnostic WBS performed a year
after thyroid ablation is necessary for this purpose. At
present, only patients of group II treated with LT4 with-
drawal have completed this step.
Conclusions
rhTSH may be safely used for 131I thyroid remnant abla-
tion in low-risk DTC patients.
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